CTOs on the Move

PellePharm

www.pellepharm.com

 
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.pellepharm.com
  • 275 Middlefield Road Suite 100
    Menlo Park, CA USA 94025
  • Phone: 510.502.6144

Executives

Name Title Contact Details

Funding

PellePharm raised $20M on 08/01/2017
PellePharm raised $70M on 11/20/2018

Similar Companies

IVFCRYO

Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.

Biolin Scientific

Biolin Scientific is a Linthicum Heights, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laronde

Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies.

Pharmaessentia

PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking.